Foghorn Therapeutics Holds 2026 Annual Meeting; Directors Elected

What Happened Foghorn Therapeutics announced the results of its June 24, 2026 Annual Meeting of Stockholders. Stockholders elected three Class III directors — Douglas Cole, M.D.; Balkrishan (Simba) Gill, Ph.D.; and B. Lynne Parshall — to three-year terms; ratified Deloitte & Touche LLP as the company’s independent registered public accounting firm for fiscal 2026; approved, on an advisory basis, the compensation of the company’s named executive officers; and voted to hold future advisory votes on executive compensation every one year. 58,713,922 shares were entitled to vote and 51,708,896 shares were present or represented by proxy.

Key Details

• Director elections (terms through 2029):
  • Douglas Cole, M.D.: For 35,118,798; Against 10,987,092; Abstentions 5,562; Broker non-votes 5,597,444.
  • Simba Gill, Ph.D.: For 45,956,872; Against 151,145; Abstentions 3,435; Broker non-votes 5,597,444.
  • B. Lynne Parshall: For 44,412,258; Against 1,695,530; Abstentions 3,664; Broker non-votes 5,597,444.
• Ratification of auditor: Deloitte & Touche LLP ratified — For 51,661,238; Against 47,431; Abstentions 227.
• Advisory votes on pay:
  • Say-on-pay approved — For 45,637,005; Against 468,947; Abstentions 5,500; Broker non-votes 5,597,444.
  • Say-on-frequency approved for “one year” — One Year 45,574,407; Two Years 3,577; Three Years 520,621; Abstentions 12,847; Broker non-votes 5,597,444.
• Proxy Statement describing the proposals was filed April 30, 2026.

Why It Matters These results confirm the company’s governance slate and auditor for fiscal 2026, providing continuity in leadership and financial oversight. The advisory approval of executive compensation and the one‑year frequency vote mean investors will have an annual say on pay (non‑binding), which can affect future compensation disclosures and governance engagement. For investors, the votes and turnout figures provide a snapshot of shareholder support and potential dissent on specific directors.